Dataset Information

Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?

ABSTRACT:

Objective

We performed this study to assess the effect of an antiplatelet agent on the progression of white matter hyperintensities (WMH).

Methods

From August 2003 to May 2005, we consecutively enrolled patients who underwent brain magnetic resonance imaging (MRI) for health check-up purposes and showed no significant findings other than WMH of any degree. Patients were divided into two groups based on whether or not they received antiplatelet therapy. All patients had a follow-up brain MRI after 5 years and WMH volume change was measured using imaging analysis software. To minimize selection bias potentially arising from antiplatelet treatment assignment, analyses were inverse probability weighted.

Results

Among the 93 patients who met the inclusion criteria, 54 patients (58.1%) were grouped as the antiplatelet group (AG), and the remaining 39 patients (41.9%) as the non-antiplatelet group (NAG). After inverse propensity weighting, all baseline characteristics were similar between the two groups, and antiplatelet treatment did not show any significant effect on the total WMH volume change (p = 0.957).

Conclusion

Antiplatelet medication may not alter the progression of WMH.

SUBMITTER: Yoon CW

PROVIDER: S-EPMC5398663 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?

Yoon Cindy W CW Choi Yoonjae Y Jeon Seun S Lee Dae Hyung DH Yoon Byung-Nam BN Park Hee-Kwon HK Rha Joung-Ho JH

PloS one 20170420 4

<h4>Objective</h4>We performed this study to assess the effect of an antiplatelet agent on the progression of white matter hyperintensities (WMH).<h4>Methods</h4>From August 2003 to May 2005, we consecutively enrolled patients who underwent brain magnetic resonance imaging (MRI) for health check-up purposes and showed no significant findings other than WMH of any degree. Patients were divided into two groups based on whether or not they received antiplatelet therapy. All patients had a follow-up ...[more]

PMID: 28426738

Similar Datasets

Project description:ImportanceProgressive parkinsonism is common in older adults without a diagnosis of Parkinson disease and is associated with adverse health outcomes, but its pathologic basis is controversial.ObjectiveTo examine if the burden of cerebral white matter hyperintensity (WMH), a common manifestation of cerebrovascular disease pathologies, is associated with the rate of progressive parkinsonism.Design, setting, and participantsThis community-based cohort study included participants recruited in 3 ongoing cohorts that began enrollment in 1994, 1997, and 2004. Prior to death, participants were observed for a mean of 7.5 years, with annual clinical assessments. From 4427 participants enrolled in the 3 cohorts, 2134 died. Postmortem autopsy was performed in 1725 decedents, and 598 also had ex vivo brain magnetic resonance imaging. Participants were excluded if they were missing any of the 9 postmortem pathology indices (n = 22) or repeated parkinsonism assessment (n = 41) or had received a clinical diagnosis of Parkinson disease at any point before or during the study (n = 19). Data were analyzed from April 2020 to August 2021.ExposuresWMH burden was assessed using a modified Fazekas rating scale.Main outcomes and measuresParkinsonism was assessed annually using 26 items of a modified motor portion of the Unified Parkinson's Disease Rating Scale. A summary score was developed from the item scores, with higher scores indicating more severe parkinsonism.ResultsOf 516 included decedents, 364 (70.5%) were female, and the mean (SD) age at death was 90.2 (6.4) years. Higher WMH was associated with faster progressive parkinsonism (estimate, 0.024; SE, 0.008; P = .002). The attenuation of this association was greater when controlling for indices of cerebrovascular disease pathologies than when controlling for neurodegenerative pathologies (cerebrovascular disease: estimate, 0.019; SE, 0.008; P = .02; neurodegenerative: estimate, 0.022; SE, 0.008; P = .003), but both remained significant.Conclusions and relevanceIn this cohort study, higher levels of both WMH and indices of cerebrovascular disease pathologies in aging brains were associated with more rapid progressive parkinsonism. Further studies are needed to determine if in vivo brain imaging of older adults for evidence of WMH and aggressive medical treatment of vascular risk factors and diseases can reduce the occurrence or severity of late-life parkinsonism.

Dataset Information

Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?

Objective

Methods

Results

Conclusion

Publications

Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets